KREBSBIO · NSE
Krebs Biochemicals and Industries Limited
₹57.54
+1.20% (+₹0.68)
Prev. close
₹56.86
Volume
3,816
Delivery %
31.8%
As of
23 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Krebs Biochemicals and Industries Limited
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is based in Visakhapatnam, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Manish Kumar Jain
Headquarters
Visakhapatnam
Employees
142
Website
krebsbiochem.comExchange
View on NSE ↗Key stats
Market cap
₹124.06 Cr
EPS (TTM)
₹-6.53
Beta (1Y · daily vs NIFTY 50)
1.19
Beta (5Y · monthly vs NIFTY 50)
2.07
Shares float
40.75 L
EPS · quarter ended Jun 2026
₹-1.15
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹53.70 Cr | ₹52.94 Cr | ₹52.13 Cr | ₹50.42 Cr | ₹43.31 Cr | ₹23.73 Cr | |
| EBITDA | ₹-16.96 Cr | ₹-32.84 Cr | ₹-15.16 Cr | ₹-8.27 Cr | ₹-14.32 Cr | ₹-3.42 Cr |
| ₹-28.36 Cr | ₹-44.53 Cr | ₹-24.69 Cr | ₹-19.73 Cr | ₹-26.94 Cr | ₹-16.93 Cr | |
| Diluted EPS | ₹-14.53 | ₹-20.81 | ₹-11.3 | ₹-9.16 | ₹-12.49 | ₹-7.85 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹159.00 Cr | ₹190.00 Cr | ₹175.00 Cr | ₹178.00 Cr | ₹169.00 Cr | ₹163.00 Cr | |
| — | — | ₹228.37 Cr | ₹238.68 Cr | ₹212.21 Cr | ₹269.84 Cr | |
| Stockholders' equity | ₹-42.00 Cr | ₹-75.00 Cr | ₹-99.00 Cr | ₹-119.00 Cr | ₹-146.00 Cr | ₹-162.00 Cr |
Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹-11.62 Cr | ₹-17.22 Cr | ₹-24.71 Cr | ₹2.36 Cr | ₹-7.89 Cr | ₹-1.92 Cr | |
| Investing cash flow | ₹-25.51 Cr | ₹-22.90 Cr | ₹-12.65 Cr | ₹-7.82 Cr | ₹-4.97 Cr | ₹-3.64 Cr |
| ₹37.66 Cr | ₹39.51 Cr | ₹37.34 Cr | ₹5.56 Cr | ₹12.86 Cr | ₹5.54 Cr | |
| Capital expenditure | ₹-25.51 Cr | ₹-27.08 Cr | ₹-10.87 Cr | ₹-9.42 Cr | ₹-3.56 Cr | ₹-4.00 Cr |
| End cash position | ₹71.07 L | ₹10.06 L | ₹8.58 L | ₹13.74 L | ₹14.16 L | ₹12.91 L |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 26(20Q) |
|---|---|
| Promoter | 72.74% |
| Public | 27.26% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| Krebs Biochemicals and Industries Limited | ₹122.59 Cr | ₹57.54 | — | — | — | — | -45.2% | -25.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Krebs Biochemicals and Industries Q2 Results FY27 Preview: Results Date, Expectations and a Look at the Numbers
Univest · 6 days ago